An FDA Advisory Committee Votes “Yes” to 6 Main Peptides for Prescriptions…Stay Tuned.

Last week, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend that six peptides become eligible for compounding by licensed pharmacies:

  • BPC-157

  • TB-500 (Thymosin Beta-4 fragment)

  • KPV

  • MOTS-c

  • Semax

  • Epitalon

The committee rejected Emideltide (DSIP).

This is significant because, if the FDA accepts the recommendations, these peptides could be legally compounded by qualified pharmacies with a prescription, making them much easier for patients to obtain through physicians rather than from unregulated online vendors.

However, there are several important points:

  • The committee's vote is advisory only. The FDA has not made a final decision yet.

  • These peptides are not FDA-approved drugs. Even if they become eligible for compounding, that does not mean the FDA has determined they are safe and effective for their proposed uses.

  • FDA career scientists previously recommended against broader access for several of these peptides, citing limited human clinical evidence on safety and efficacy.

In practical terms:

  • Today: Most of these peptides remain difficult to obtain legally through compounding pharmacies.

  • Potentially in the future: If the FDA adopts the committee's recommendations, physicians could prescribe compounded versions from licensed pharmacies, creating a more regulated alternative to the current gray market. The FDA's final decision could take months or longer.